AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...
A woman who is at least the fourth generation of her family to suffer a "cruel" brain disorder, which leaves people trapped ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
Hosted on MSN7d
New OHSU study examines potential link between PTSD, sleep issues and Parkinson's diseaseResearchers at Oregon Health & Science University (OHSU) are leading a study looking at a possible link between thrashing ...
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
Jan. 21, 2025 — The B vitamin mitigates manganese neurotoxicity, which produces symptoms that resemble Parkinson's disease. The vitamin improves dopamine production in the brain and offers ...
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback